202 related articles for article (PubMed ID: 24632820)
1. A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas LG; Jerez JM; Carmona R; de Luque V; Vicioso L; Claros MG; Viguera E; Pajares B; Sánchez A; Ribelles N; Alba E; Lozano J
PLoS One; 2014; 9(3):e91884. PubMed ID: 24632820
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study.
Marino AL; Evangelista AF; Vieira RA; Macedo T; Kerr LM; Abrahão-Machado LF; Longatto-Filho A; Silveira HC; Marques MM
BMC Cancer; 2014 Oct; 14():739. PubMed ID: 25277099
[TBL] [Abstract][Full Text] [Related]
3. Ensemble-based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long-term risk of metastases.
Block I; Burton M; Sørensen KP; Larsen MJ; Do TTN; Bak M; Cold S; Thomassen M; Tan Q; Kruse TA
Cancer Med; 2024 May; 13(9):e7089. PubMed ID: 38676390
[TBL] [Abstract][Full Text] [Related]
4. Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition.
Cava C; Bertoli G; Ripamonti M; Mauri G; Zoppis I; Della Rosa PA; Gilardi MC; Castiglioni I
PLoS One; 2014; 9(5):e97681. PubMed ID: 24866763
[TBL] [Abstract][Full Text] [Related]
5. A tissue microRNA signature that predicts the prognosis of breast cancer in young women.
Hironaka-Mitsuhashi A; Matsuzaki J; Takahashi RU; Yoshida M; Nezu Y; Yamamoto Y; Shiino S; Kinoshita T; Ushijima T; Hiraoka N; Shimizu C; Tamura K; Ochiya T
PLoS One; 2017; 12(11):e0187638. PubMed ID: 29141042
[TBL] [Abstract][Full Text] [Related]
6. Novel Predictors of Breast Cancer Survival Derived from miRNA Activity Analysis.
Aushev VN; Lee E; Zhu J; Gopalakrishnan K; Li Q; Teitelbaum SL; Wetmur J; Degli Esposti D; Hernandez-Vargas H; Herceg Z; Parada H; Santella RM; Gammon MD; Chen J
Clin Cancer Res; 2018 Feb; 24(3):581-591. PubMed ID: 29138345
[No Abstract] [Full Text] [Related]
7. Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data.
Shen R; Ghosh D; Chinnaiyan AM
BMC Genomics; 2004 Dec; 5(1):94. PubMed ID: 15598354
[TBL] [Abstract][Full Text] [Related]
8. A clustering-based approach for efficient identification of microRNA combinatorial biomarkers.
Yang Y; Huang N; Hao L; Kong W
BMC Genomics; 2017 Mar; 18(Suppl 2):210. PubMed ID: 28361698
[TBL] [Abstract][Full Text] [Related]
9. Identification of glycogene-based prognostic signature and validation of B3GNT7 as a potential biomarker and therapeutic target in breast cancer.
Wang X; Wang Y; Chen X; He Y; Zhou X; Jiao S; Zhu Z; Wu C; Bao J
J Cancer Res Clin Oncol; 2023 Dec; 149(19):16957-16969. PubMed ID: 37740763
[TBL] [Abstract][Full Text] [Related]
10. Dormancy in Breast Cancer.
Dalla E; Sreekumar A; Aguirre-Ghiso JA; Chodosh LA
Cold Spring Harb Perspect Med; 2023 Nov; 13(11):. PubMed ID: 37037598
[TBL] [Abstract][Full Text] [Related]
11. A miRNA signature assessing ovarian cancer prognosis.
Bagnoli M; Pignata S; Mezzanzanica D
Oncoscience; 2016; 3(11-12):308-310. PubMed ID: 28105451
[No Abstract] [Full Text] [Related]
12. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
13. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
14. Technology in MicroRNA Profiling: Circulating MicroRNAs as Noninvasive Cancer Biomarkers in Breast Cancer.
Pimentel F; Bonilla P; Ravishankar YG; Contag A; Gopal N; LaCour S; Lee T; Niemz A
J Lab Autom; 2015 Oct; 20(5):574-88. PubMed ID: 25524488
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer-Specific miR Signature Unique to Extracellular Vesicles Includes "microRNA-like" tRNA Fragments.
Guzman N; Agarwal K; Asthagiri D; Yu L; Saji M; Ringel MD; Paulaitis ME
Mol Cancer Res; 2015 May; 13(5):891-901. PubMed ID: 25722304
[TBL] [Abstract][Full Text] [Related]
16. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring.
McGuire A; Brown JA; Kerin MJ
Cancer Metastasis Rev; 2015 Mar; 34(1):145-55. PubMed ID: 25721950
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA signatures highlight new breast cancer subtypes.
Bhattacharyya M; Nath J; Bandyopadhyay S
Gene; 2015 Feb; 556(2):192-8. PubMed ID: 25485717
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.
Khan S; Wall D; Curran C; Newell J; Kerin MJ; Dwyer RM
BMC Cancer; 2015 May; 15():345. PubMed ID: 25934412
[TBL] [Abstract][Full Text] [Related]
19. Use of serum-circulating miRNA profiling for the identification of breast cancer biomarkers.
Mar-Aguilar F; Rodríguez-Padilla C; Reséndez-Pérez D
Methods Mol Biol; 2014; 1165():71-80. PubMed ID: 24839019
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential.
Kumar S; Nag A; Mandal CC
Curr Drug Targets; 2015; 16(12):1381-403. PubMed ID: 25808651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
